Clinical UM Guideline

This document provides clinical criteria for use of outpatient infusion therapy service in the hospital outpatient department or hospital outpatient clinic site of care for intravenous (IV) infusion and injectable therapy.

Note: In some plans, “level of care,” “site of service” or another term such as “setting” or “place of service” may be the term used in benefit plans, provider contracts, or other materials instead of or in addition to “site of care” and, in some plans, these terms may be used interchangeably.

Note: Please see the following related documents for additional information:

• CG-MED-23 Home Health
• CG-SURG-10 Ambulatory or Outpatient Surgery Center Procedures

Note: For a high-level overview of this document, please see “Summary for Members and Families” below. 

Note: The medical necessity of the infused pharmacologic or biologic agent may be separately reviewed against the appropriate criteria. This guideline is for determination of the medical necessity of hospital outpatient site of care for the IV infusion and injectable therapy.

Medically Necessary:

An outpatient IV infusion or injectable therapy service in the hospital outpatient department or hospital outpatient clinic site of care for the use of an infused pharmacologic or biologic agent is considered medically necessary when all of the following are present:

1. The inherent complexity or risk of the infusion required by an individual is such that it can be performed safely and effectively only by or under the general supervision of skilled nursing personnel; and
2. The individual's medical status or therapy is such that it requires enhanced monitoring beyond that which would routinely be needed for infusion therapy; and
3. The potential changes in the individual’s clinical condition are such that immediate access to specific services of a medical center/hospital setting, having emergency resuscitation equipment and personnel, and inpatient admission or intensive care is necessary, for example, the individual is at significant risk of sudden life-threatening changes in medical status based on clinical conditions including but not limited to:
   1. Concerns regarding fluid overload status; or
   2. History of anaphylaxis to prior infusion therapy with a related pharmacologic or biologic agent; or
   3. Acute mental status changes.

An outpatient IV infusion or injectable therapy service in the hospital outpatient department or hospital outpatient clinic site of care for the use of an infused pharmacologic or biologic agent is considered medically necessary when there are no other geographically accessible appropriate alternative sites for the individual to undergo the IV infusion or injectable therapy service.

Not Medically Necessary:

All other uses of outpatient IV infusion and injectable therapy services in the hospital outpatient department or hospital outpatient clinic site of care for the infusion of pharmacologic and biologic agents are considered not medically necessary.

This document describes clinical studies and expert recommendations, and explains when injectable or IV therapy in the hospital outpatient department or clinic is clinically appropriate. The following summary does not replace the medical necessity criteria or other information in this document. The summary may not contain all of the relevant criteria or information. This summary is not medical advice. Please check with your healthcare provider for any advice about your health.

Key Information

Outpatient intravenous (IV) infusion and injectable therapy involves giving medicines through a vein or by injection without staying overnight in the hospital. These medicines may include drugs or biologic medicines (medicines made from living cells). Many people can safely receive these treatments at home, in a doctor's office, or at an infusion center. However, some people need treatment in a hospital outpatient department or hospital outpatient clinic because they have a higher risk of serious problems during treatment or need closer monitoring. A hospital setting provides trained nursing staff, emergency equipment, and rapid access to hospital care if needed.

What the Studies Show

Many studies have found that IV infusion therapy can be given safely in places other than a hospital for people who are not at high risk of having a reaction to therapy. Research has shown that treatment at home, in a doctor's office, or at an infusion center can provide similar safety and treatment results for many adults. One study comparing hospital outpatient treatment with other care settings found no meaningful differences in infusion-related side effects, emergency department visits, or long-term medicine use for appropriately selected people. Better studies are needed to know whether hospital treatment improves health for people who do not have higher medical risks.

Experts recommend choosing the treatment setting based on a careful review of each person's health and treatment needs. A hospital outpatient setting may be safer for people starting certain high-risk medicines, receiving medicines with a known risk of severe allergic reactions, needing rapid dose changes, having unstable health, or lacking a safe home environment for treatment. For children, age alone should not determine where treatment is given. Instead, the decision should be based on the child's health, caregiver training, and whether safe home infusion services are available. Receiving treatment in a hospital may reduce the risk of delayed emergency care for people with serious medical needs, but it may also require more travel and time than other settings.

When is Hospital Outpatient IV Infusion or Injectable Therapy Clinically Appropriate?

Hospital outpatient IV infusion or injectable therapy may be appropriate in these situations:

• The infusion is complex or carries enough risk that it can be safely given only by, or under the supervision of, skilled nursing staff; and
• The person's medical condition or treatment requires closer monitoring than is usually needed during infusion therapy; and
• The person may have sudden, life-threatening changes that require immediate access to emergency equipment, hospital staff, or hospital admission. Examples include:
  • Concerns about fluid overload; or
  • A previous severe allergic reaction, including anaphylaxis, to a related infused medicine; or
  • Sudden changes in mental status.

Hospital outpatient IV infusion or injectable therapy may also be appropriate when there is no other suitable treatment location that is reasonably accessible.

When is Hospital Outpatient IV Infusion or Injectable Therapy not Clinically appropriate?

Hospital outpatient IV infusion or injectable therapy is not clinically appropriate in situations other than those listed above. 

Using a hospital outpatient setting when these higher-risk needs are not present has not been shown to improve health. Choosing a hospital setting without medical need may expose people to more intensive care than necessary without proven additional benefit.

(Return to Description)

Coding edits for medical necessity review are not implemented for this guideline. Where a more specific policy or guideline exists, that document will take precedence and may include specific coding edits and/or instructions. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Summary

This document outlines clinical criteria for use of outpatient infusion therapy service in the hospital outpatient department or hospital outpatient clinic for intravenous (IV) infusion and injectable therapy (in contrast to an alternate site, such as the home or an ambulatory infusion center). Hospital-based infusion is considered medically necessary only when a structured clinical risk assessment identifies needs such as enhanced monitoring and immediate access to emergency care, or the absence of any geographically accessible alternative site of care. The document integrates standards from the Infusion Therapy Standards of Practice, 2024, with considerations for first-dose reactions, complex drug profiles, pediatric requirements, and environmental or caregiver factors that may preclude safe administration in lower-acuity settings.

Discussion

Infusion therapy (pharmacologic or biologic agents) has been proven to be safely and effectively administered in an office-based setting, infusion center or the home setting. Home-based infusion, when appropriate and available, may in some cases be supported by member preference (Chataway, 2006; Milligan, 2006; Riazi, 2011). Hospital outpatient administration of IV medications may be appropriate for complex infusions requiring direct observation or the minimization of certain treatment risks that require hospital-based therapy when criteria are met.

The hospital outpatient department or hospital outpatient clinic is part of a hospital but is designed for the treatment of outpatients; that is, individuals who do not require hospital admission.

The potential for severe infusion reactions poses a significant safety risk to certain individuals with a history of previous severe infusion reactions, including anaphylaxis to prior infusion therapy with a related pharmacologic or biologic agent and should be considered when identifying the appropriate site of care for the administration an IV infusion or injectable therapy service. The risk assessment should include consideration of whether immediate access to specific services of a medical center/hospital setting, including emergency resuscitation equipment and personnel are needed, as well as the need for inpatient admission or intensive care services.

Home Infusion as an Alternative to Facility-Based Infusion

The Infusion Nurses Society (INS) updated their comprehensive Infusion Therapy Standards of Practice in 2024 (INS, 2024). Standard 66 in that document indicates that a home may be an appropriate infusion setting when a structured risk-assessment shows that factors associated with the infusion program, infusion recipient, caregivers, environment, and drug profile all align with safety criteria. The standards note that infusion therapy should occur in a monitored healthcare facility when:

• The drug is classed as high-risk or requires real-time titration such as continuous vasoactive agents, antineoplastics, or moderate-sedation/analgesia infusions; or
• The requested treatment episode involves a first-dose or sensitizing infusion of an agent with recognized anaphylaxis potential (for example, monoclonal antibodies, enzyme-replacement therapies, new antimicrobial classes); or
• Immunoglobulin therapy is being started; or
• The infusion recipient’s clinical status is unstable, rapid dosage adjustment is anticipated, vascular access is unreliable, or environmental/caregiver factors preclude safe pump operation and emergency response.

Environmental factors, including those affecting caregivers and clinician safety, should be evaluated as part of the care setting decision. These considerations may include, but are not limited to, circumstances such as substance use in the home, aggressive animals, or abusive or threatening behaviors (Gorski, 2024).

Pediatric Considerations

Initiating home infusion therapy for children is not inherently unsafe, nor is it prohibited by national standards. Current evidence and the INS 2024 Infusion Therapy Standards of Practice support home infusion therapy initiation when a child is clinically stable, caregivers are well trained, and a pediatric-experienced home-infusion team is available. Structured risk assessment as noted above, not age alone, should guide the site-of-care decision (Gorski, 2024; INS, 2024).

Geographically accessible: The ease of reaching a destination; the concept takes into account multiple factors, including, but not limited to, distance to and time required to get to a specific location and the logistical complexity of transport.

Peer Reviewed Publications:

1. Chataway J, Porter B, Riazi A, et al. Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomized controlled trial. Lancet Neurol. 2006; 5(7):565-571.
2. Gutierrez-Aguirre CH, Ruiz-Arguelles G, Cantu-Rodriguez OG, et al. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. Ann Hematol. 2010; 89(10):1045-1052.
3. Mank A, van der Lelie J, de Vos R, Kersten MJ. Safe early discharge for patients undergoing high dose chemotherapy with or without stem cell transplantation: a prospective analysis of clinical variables predictive for complications after treatment. J Clin Nurs. 2011; 20(3-4):388-395.
4. Milligan A, Hughes D, Goodwin S, et al. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006; 15(6):330-333.
5. Riazi A, Porter B, Chataway J, et al. A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse management Scale (MSRMS). Health Qual Life Outcomes. 2011; 9:80.
6. Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol. 2011; 22(11):2358-2365.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. December 2011. Available at: http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20Resources/Guidelines-for-the-site-of-care-for-administration-of-IGIV-therapy.pdf. Accessed on July 11, 2026.
2. Broyles AD, Banerji A, Barmettler S, et al. Practical guidance for the evaluation and management of drug hypersensitivity: Specific drugs. J Allergy Clin Immunol Pract. 2020; 8(95):S16-S116.
3. Gorski LA. Update: the 2024 infusion therapy standards of practice. Home Healthc Now. 2024; 42(4):198-205.
4. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020; 38(24):2782-2797.
5. Infusion Nurses Society (INS). Infusion therapy standards of practice. J Infus Nurs. 2024; 47(1S Suppl):S1-S224.
6. NCCN Clinical Practice Guidelines in Oncology^®. ^© 2026 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Accessed on July 11, 2026.
   • Antiemesis (V.2.2026). Revised June 24, 2026.
   • Prevention and Treatment of Cancer-Related Infections. (V.1.2026) Revised March 11, 2026.

1. National Home Infusion Association. About home and specialty infusion. Available at: https://www.nhia.org/about-infusion-therapy/. Accessed on. July 11, 2026.

Infusion therapy
Injectable therapy
Site of care
Specialty pharmaceuticals

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.